Literature DB >> 30075967

Exercise hemodynamics in hypertrophic cardiomyopathy identify risk of incident heart failure but not ventricular arrhythmias or sudden cardiac death.

Eric D Smith1, June Tome2, Ryan Mcgrath1, Suwen Kumar3, Maryann Concannon1, Sharlene M Day4, Sara Saberi5, Adam S Helms6.   

Abstract

OBJECTIVE: To determine whether abnormal blood pressure response (ABPR), with or without left ventricular outflow tract obstruction (LVOTO), is associated with adverse heart failure and arrhythmia outcomes in hypertrophic cardiomyopathy (HCM).
METHODS: A retrospective, single-center analysis was performed for adult HCM patients who underwent exercise stress testing.
RESULTS: Of 589 patients included in the study, 192 (33%) demonstrated ABPR. A similar proportion of patients with ABPR had LVOTO compared to those without ABPR (56% vs 63%, p = 0.11). Patients with ABPR demonstrated lower percent predicted VO2 and METs achieved than those with LVOTO (16.9 ± 6.8 vs 21.6 ± 7.9, p = 0.002 and 5.3 ± 2.4 vs 7.4 ± 3.1, p < 0.001). In a subgroup of 17 patients with LVOTO and ABPR who subsequently underwent successful myectomy, 5 (30%) demonstrated persistent ABPR. 23 patients (3.8%) experienced sudden cardiac death or ventricular arrhythmias, which were not associated with ABPR, regardless of age group. In multivariable analysis, syncope (p = 0.04), left ventricular hypertrophy (p = 0.02) and left atrial diameter (p = 0.006) were significantly associated with the composite outcome of sudden death or severe ventricular arrhythmia, whereas ABPR was not (p = 0.38). In contrast, ABPR was associated with subsequent heart failure hospitalization (p = 0.002), regardless of presence or absence of LVOTO (p = 0.04, p = 0.02).
CONCLUSIONS: ABPR is associated with reduced functional capacity in HCM regardless of the presence of LVOTO but is not associated with adverse arrhythmia outcomes. Patients with ABPR have a higher incidence of subsequent heart failure hospitalization.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Abnormal blood pressure response; Heart failure; Hypertrophic cardiomyopathy; Sudden cardiac death

Mesh:

Year:  2018        PMID: 30075967     DOI: 10.1016/j.ijcard.2018.07.110

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  3 in total

1.  MitraClip implantation in non-obstructive hypertrophic cardiomyopathy: the ever-expanding landscape of transcatheter edge-to-edge repair.

Authors:  Claudio Montalto; Panagiotis Xaplanteris
Journal:  Eur Heart J Case Rep       Date:  2022-01-09

2.  Prognostic Value of Reduced Heart Rate Reserve during Exercise in Hypertrophic Cardiomyopathy.

Authors:  Quirino Ciampi; Iacopo Olivotto; Jesus Peteiro; Maria Grazia D'Alfonso; Fabio Mori; Luigi Tassetti; Alessandra Milazzo; Lorenzo Monserrat; Xusto Fernandez; Attila Pálinkás; Eszter Dalma Pálinkás; Róbert Sepp; Federica Re; Lauro Cortigiani; Milorad Tesic; Ana Djordjevic-Dikic; Branko Beleslin; Mariangela Losi; Grazia Canciello; Sandro Betocchi; Luis Rocha Lopes; Ines Cruz; Carlos Cotrim; Marco A R Torres; Clarissa C A Bellagamba; Caroline M Van De Heyning; Albert Varga; Gergely Ágoston; Bruno Villari; Valentina Lorenzoni; Clara Carpeggiani; Eugenio Picano
Journal:  J Clin Med       Date:  2021-03-24       Impact factor: 4.241

3.  Prognostic relevance of exercise testing in hypertrophic cardiomyopathy. A systematic review.

Authors:  Tiago Rodrigues; Sofia Cavaco Raposo; Dulce Brito; Luis R Lopes
Journal:  Int J Cardiol       Date:  2021-06-30       Impact factor: 4.039

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.